This company has been marked as potentially delisted and may not be actively trading. Bioblast Pharma (ORPN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsHeadlinesTrendsBuy This Stock ORPN vs. EYEN, PLRZ, BPTH, PCSA, SLRX, SXTC, ASLN, CWBR, BPTSY, and APVOShould you be buying Bioblast Pharma stock or one of its competitors? The main competitors of Bioblast Pharma include Eyenovia (EYEN), Polyrizon (PLRZ), Bio-Path (BPTH), Processa Pharmaceuticals (PCSA), Salarius Pharmaceuticals (SLRX), China SXT Pharmaceuticals (SXTC), ASLAN Pharmaceuticals (ASLN), CohBar (CWBR), Biophytis (BPTSY), and Aptevo Therapeutics (APVO). These companies are all part of the "medical" sector. Bioblast Pharma vs. Eyenovia Polyrizon Bio-Path Processa Pharmaceuticals Salarius Pharmaceuticals China SXT Pharmaceuticals ASLAN Pharmaceuticals CohBar Biophytis Aptevo Therapeutics Eyenovia (NASDAQ:EYEN) and Bioblast Pharma (NASDAQ:ORPN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment. Does the media prefer EYEN or ORPN? In the previous week, Eyenovia's average media sentiment score of 0.00 equaled Bioblast Pharma'saverage media sentiment score. Company Overall Sentiment Eyenovia Neutral Bioblast Pharma Neutral Do analysts rate EYEN or ORPN? Eyenovia presently has a consensus target price of $2.00, indicating a potential upside of 70.94%. Given Eyenovia's stronger consensus rating and higher possible upside, equities research analysts plainly believe Eyenovia is more favorable than Bioblast Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eyenovia 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Bioblast Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is EYEN or ORPN more profitable? Bioblast Pharma has a net margin of 0.00% compared to Eyenovia's net margin of -114,639.41%. Bioblast Pharma's return on equity of 0.00% beat Eyenovia's return on equity.Company Net Margins Return on Equity Return on Assets Eyenovia-114,639.41% -1,108.24% -139.36% Bioblast Pharma N/A N/A N/A Do insiders & institutionals have more ownership in EYEN or ORPN? 25.8% of Eyenovia shares are owned by institutional investors. Comparatively, 4.5% of Bioblast Pharma shares are owned by institutional investors. 7.1% of Eyenovia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has more risk and volatility, EYEN or ORPN? Eyenovia has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. Comparatively, Bioblast Pharma has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Which has better earnings & valuation, EYEN or ORPN? Bioblast Pharma has lower revenue, but higher earnings than Eyenovia. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEyenovia$57.34K57.75-$27.26M-$58.40-0.02Bioblast PharmaN/AN/A-$5.94MN/AN/A Does the MarketBeat Community prefer EYEN or ORPN? Bioblast Pharma received 38 more outperform votes than Eyenovia when rated by MarketBeat users. Likewise, 78.23% of users gave Bioblast Pharma an outperform vote while only 64.21% of users gave Eyenovia an outperform vote. CompanyUnderperformOutperformEyenoviaOutperform Votes17464.21% Underperform Votes9735.79% Bioblast PharmaOutperform Votes21278.23% Underperform Votes5921.77% SummaryBioblast Pharma beats Eyenovia on 7 of the 12 factors compared between the two stocks. Get Bioblast Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ORPN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORPN vs. The Competition Export to ExcelMetricBioblast PharmaPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$437,000.00$6.86B$5.56B$8.03BDividend YieldN/A2.90%5.36%4.22%P/E RatioN/A7.5422.7918.88Price / SalesN/A259.70406.35106.93Price / CashN/A65.8538.1834.62Price / Book0.146.566.794.34Net Income-$5.94M$143.88M$3.23B$248.14M Bioblast Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORPNBioblast PharmaN/A$1.04-1.0%N/A-35.8%$437,000.00N/A0.00N/AHigh Trading VolumeEYENEyenovia2.5532 of 5 stars$1.09+0.0%$2.00+83.5%-98.6%$1.52M$57,336.00-0.0240Short Interest ↓Positive NewsPLRZPolyrizonN/A$0.33+3.1%N/AN/A$1.38MN/A0.00N/ALockup ExpirationGap UpBPTHBio-Path2.1148 of 5 stars$0.16+16.7%$20.00+12,598.4%-94.3%$1.31MN/A0.0010News CoverageGap UpPCSAProcessa Pharmaceuticals2.6074 of 5 stars$0.24+8.4%$6.00+2,408.4%-89.3%$1.26MN/A-0.0720Upcoming EarningsNews CoverageGap DownSLRXSalarius Pharmaceuticals0.8132 of 5 stars$0.72+9.1%N/A-82.6%$1.24MN/A-0.0920Short Interest ↓SXTCChina SXT Pharmaceuticals0.5186 of 5 stars$1.70-18.3%N/A-70.3%$1.23M$1.82M0.0090Gap UpHigh Trading VolumeASLNASLAN PharmaceuticalsN/A$0.60flat$72.00+11,900.0%N/A$1.23M$12M-0.0330CWBRCohBarN/A$0.41flatN/AN/A$1.19MN/A0.0010BPTSYBiophytisN/A$3.36flatN/AN/A$1.18MN/A0.0030APVOAptevo Therapeutics1.576 of 5 stars$0.74+6.7%$10,952.00+1,479,900.0%-100.0%$1.08M$3.11M0.0050Upcoming Earnings Related Companies and Tools Related Companies Eyenovia Competitors Polyrizon Competitors Bio-Path Competitors Processa Pharmaceuticals Competitors Salarius Pharmaceuticals Competitors China SXT Pharmaceuticals Competitors ASLAN Pharmaceuticals Competitors CohBar Competitors Biophytis Competitors Aptevo Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORPN) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredWhy Elon put $51 million into thisWhile fear dominates the headlines, a silent breakthrough could turn panic into profit. The future of AI fa...True Market Insiders | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioblast Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioblast Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ORPN Stock Free ORPN Stock Alerts